NEWS
NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
NeuroBo Pharmaceuticals (Nasdaq: NRBO) has completed enrollment for Part 1 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin analog agonist for obesity treatment. The single ascending dose (SAD) study enrolled 45 participants across 5 cohorts. No significant issues were encountered, allowing an accelerated start to the multiple ascending dose (MAD) Part 2.
Key points:
Top-line data from SAD Part 1 expected in Q3 2024
MAD Part 2 results anticipated in Q1 2025
Pre-clinical data showed superior weight loss compared to semaglutide and tirzepatide
DA-1726 may become a best-in-class obesity drug with better tolerability
Part 3 of the trial planned to start in Q3 2025, with interim data expected mid-2026 and top-line results in H2 2026
NeuroBo Pharmaceuticals (Nasdaq: NRBO) has completed enrollment for Part 1 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin analog agonist for obesity treatment. The single ascending dose (SAD) study enrolled 45 participants across 5 cohorts. No significant issues were encountered, allowing an accelerated start to the multiple ascending dose (MAD) Part 2.
Key points:
Top-line data from SAD Part 1 expected in Q3 2024
MAD Part 2 results anticipated in Q1 2025
Pre-clinical data showed superior weight loss compared to semaglutide and tirzepatide
DA-1726 may become a best-in-class obesity drug with better tolerability
Part 3 of the trial planned to start in Q3 2025, with interim data expected mid-2026 and top-line results in H2 2026
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1876Followers
99Following
16KVisitors
Follow